Vikram Purohit
Stock Analyst at Morgan Stanley
(1.81)
# 3,310
Out of 5,148 analysts
163
Total ratings
32.31%
Success rate
-7.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Maintains: Overweight | $11 → $18 | $7.02 | +156.41% | 3 | Feb 18, 2026 | |
| INCY Incyte | Maintains: Equal-Weight | $92 → $94 | $100.04 | -6.04% | 26 | Jan 6, 2026 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $31 → $34 | $25.56 | +33.02% | 3 | Oct 28, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $80 → $79 | $69.85 | +13.10% | 11 | Oct 20, 2025 | |
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $2.80 | +110.36% | 3 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $3.63 | +37.74% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $242.09 | +3.27% | 19 | May 5, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $166.38 | +14.20% | 19 | Feb 27, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $5.76 | +56.25% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $29.65 | +4.55% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $16 | $113.11 | -85.85% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $24.76 | -59.61% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $13.98 | -57.08% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $9.24 | +354.55% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $90.10 | -54.50% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $8.58 | +366.20% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $2.31 | +462.77% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $12.15 | +212.76% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $7.05 | +183.69% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $18.95 | -47.23% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.05 | +1,995.24% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $23.25 | -13.98% | 2 | Aug 5, 2020 |
COMPASS Pathways
Feb 18, 2026
Maintains: Overweight
Price Target: $11 → $18
Current: $7.02
Upside: +156.41%
Incyte
Jan 6, 2026
Maintains: Equal-Weight
Price Target: $92 → $94
Current: $100.04
Upside: -6.04%
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31 → $34
Current: $25.56
Upside: +33.02%
Halozyme Therapeutics
Oct 20, 2025
Maintains: Overweight
Price Target: $80 → $79
Current: $69.85
Upside: +13.10%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $2.80
Upside: +110.36%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $3.63
Upside: +37.74%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $242.09
Upside: +3.27%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $166.38
Upside: +14.20%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $5.76
Upside: +56.25%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $29.65
Upside: +4.55%
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $113.11
Upside: -85.85%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $24.76
Upside: -59.61%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $13.98
Upside: -57.08%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $9.24
Upside: +354.55%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $90.10
Upside: -54.50%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $8.58
Upside: +366.20%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.31
Upside: +462.77%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $12.15
Upside: +212.76%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $7.05
Upside: +183.69%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $18.95
Upside: -47.23%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.05
Upside: +1,995.24%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $23.25
Upside: -13.98%